Clinical Trial Update: QTc Study of Rosi XR in Healthy Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 QTc study of the drug Rosi XR in healthy volunteers has been withdrawn by the sponsor, GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Rosi XR

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 1 | Status: WITHDRAWN